Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ELN441958 is a bradykinin B1 receptor antagonist (Ki = 0.26 nM).1 It is selective for the bradykinin B1 receptor over a panel of greater than 100 enzymes and receptors at 10 µM but does bind to the μ-, δ-, and κ-opioid receptors and M1 muscarinic receptor (Kis = 0.13, 0.69, 1.5, and 0.37 µM, respectively). ELN441958 inhibits calcium mobilization induced by the bradykinin B1 receptor agonist (Des-Arg10)-kallidin (DAKD) in IMR-90 cells expressing the human bradykinin B1 receptor (KB = 0.12 nM). It increases tail withdrawal latencies in a rhesus monkey model of carrageenan-induced hyperalgesia when administered at doses of 3 or 10 mg/kg.
WARNING This product is not for human or veterinary use.
1. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 receptor antagonist ELN441958. J. Pharmacol. Exp. Ther. 322(2), 619-630 (2007).